Márk Plander
Impact in
- Genetics top 5%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Hematology top 10%
- Multiple Myeloma Research and Treatments
- Acute Myeloid Leukemia Research
Papers in
- Genetics 15
- Chronic Lymphocytic Leukemia Research 11
- Myeloproliferative Neoplasms: Diagnosis and Treatment 4
- Hematology 10
- Multiple Myeloma Research and Treatments 6
- Acute Myeloid Leukemia Research 2
- Co-authors
- Gero Brockhoff (4 shared papers)Ferdinand Hofstaedter (1 shared paper)Ferdinand Hofstädter (2 shared papers)Péter Ugocsai (2 shared papers)Gerd Schmitz (2 shared papers)Ruth Knüchel (1 shared paper)Simone Diermeier‐Daucher (1 shared paper)Stephan Schwarz (1 shared paper)
In The Last Decade
Márk Plander
30 papers receiving 496 citations
Márk Plander's Hit Papers
Peers
Comparison fields: 5 of 46
- Genetics 257
- Hematology 74
- Internal Medicine 10
- Oncology 62
- Pathology and Forensic Medicine 23
Countries citing papers authored by Márk Plander
This map shows the geographic impact of Márk Plander's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Márk Plander with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Márk Plander more than expected).
Fields of papers citing papers by Márk Plander
This network shows the impact of papers produced by Márk Plander. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Márk Plander. The network helps show where Márk Plander may publish in the future.
Co-authors
The 25 scholars most cited alongside Márk Plander, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 34 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study Hit paper breakdown → | 2023 | 146 |
| 2 | 2007 | 74 | |
| 3 | 2009 | 58 | |
| 4 | 2019 | 24 | |
| 5 | 2011 | 23 | |
| 6 | 2019 | 23 | |
| 7 | 2023 | 22 | |
| 8 | 2018 | 18 | |
| 9 | 2015 | 17 | |
| 10 | 2003 | 16 | |
| 11 | 2021 | 14 | |
| 12 | 2018 | 10 | |
| 13 | 2023 | 10 | |
| 14 | 2018 | 8 | |
| 15 | 2011 | 7 | |
| 16 | 2022 | 6 | |
| 17 | 2016 | 5 | |
| 18 | A TP53-mutáció-analízis jelentősége krónikus lymphocytás leukaemiában | TP53mutation analysis in chronic lymphocytic leukaemia | 2017 | 4 |
| 19 | 2021 | 4 | |
| 20 | 2023 | 3 |
About Márk Plander
Márk Plander is a scholar working on Genetics, Hematology, Pathology and Forensic Medicine, Immunology and Internal Medicine, having authored 34 papers that have together received 507 indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (11 papers), Multiple Myeloma Research and Treatments (6 papers), Lymphoma Diagnosis and Treatment (5 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers), Acute Myeloid Leukemia Research (2 papers), T-cell and B-cell Immunology (2 papers), Clinical Laboratory Practices and Quality Control (1 paper) and Dupuytren's Contracture and Treatments (1 paper). The work is most often cited by research in Genetics (257 citations), Hematology (74 citations), Internal Medicine (10 citations), Oncology (62 citations) and Pathology and Forensic Medicine (23 citations). Márk Plander has collaborated with scholars based in Hungary and Germany. Frequent co-authors include Gero Brockhoff, Ferdinand Hofstaedter, Ferdinand Hofstädter, Péter Ugocsai, Gerd Schmitz, Ruth Knüchel, Simone Diermeier‐Daucher, Stephan Schwarz, E. Orsó and Imre Bodó. Their work appears in journals such as Pathology & Oncology Research, Annals of Hematology, The Lancet, The Journal of Pathology and Hematological Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.